Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-08-26
1996-08-06
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514411, 514291, A61K 3154, A61K 3140, A61K 3144
Patent
active
055434070
ABSTRACT:
An empirical efficacy appears in the drug-withdrawal treatment of drug dependence with a novel drug-withdrawal scopolamine agent(DSA) which contains scopolamine hydrobromide as a subsidiary component. Each of the drugs may be used either combined as an injectable preparation or used integrately as separated injections for drug-withdrawal treatment.
REFERENCES:
patent: 4555397 (1985-11-01), Bachynsky
patent: 4746509 (1988-05-01), Haggiage et al.
patent: 5034400 (1991-07-01), Olney
patent: 5189064 (1993-02-01), Blum et al.
Chlorpromazine and Scopolamine in USP XXII, p. 293-294 and 1238-1239 (1990).
O'Brien, "Drug Abuse and Dependent", Cecil Textbook of Medicine, 19th ed., 47-55 (1992).
Weiner, "Atropine, Scopolamine, and Related Antimuscarinic Drugs", The Pharmacological Basis of Therapeutics, 6th ed., Goodman and Gilman Ed., 120-132, Chapter 7 (1980).
Gold et al., "Clonidine Blocks Acute Opiate-Withdrawal Symptoms", The Lancet, 599-601 (1978).
Criares Theodore J.
Ningbo Institute of Microcirculation and Henbane
LandOfFree
Preparation and application of scopolamine and chlorpromazine as does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation and application of scopolamine and chlorpromazine as, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation and application of scopolamine and chlorpromazine as will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2191215